GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » EV-to-Revenue

CTNM (Contineum Therapeutics) EV-to-Revenue : (As of Oct. 31, 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Contineum Therapeutics's enterprise value is $222.84 Mil. Contineum Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil. Therefore, Contineum Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Contineum Therapeutics's EV-to-Revenue or its related term are showing as below:

CTNM' s EV-to-Revenue Range Over the Past 10 Years
Min: 5.28   Med: 6.76   Max: 9.02
Current: 4.46

During the past 3 years, the highest EV-to-Revenue of Contineum Therapeutics was 9.02. The lowest was 5.28. And the median was 6.76.

CTNM's EV-to-Revenue is ranked better than
65.73% of 1033 companies
in the Biotechnology industry
Industry Median: 8.14 vs CTNM: 4.46

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-10-31), Contineum Therapeutics's stock price is $16.76. Contineum Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00. Therefore, Contineum Therapeutics's PS Ratio for today is .


Contineum Therapeutics EV-to-Revenue Historical Data

The historical data trend for Contineum Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics EV-to-Revenue Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-Revenue
- - -

Contineum Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of Contineum Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Contineum Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Contineum Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Contineum Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Contineum Therapeutics's EV-to-Revenue falls into.



Contineum Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Contineum Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=222.841/0
=

Contineum Therapeutics's current Enterprise Value is $222.84 Mil.
Contineum Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics  (NAS:CTNM) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Contineum Therapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=16.76/0
=

Contineum Therapeutics's share price for today is $16.76.
Contineum Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Contineum Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Contineum Therapeutics Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.